Heidari M, Shokrani P
J Med Signals Sens. 2024; 14:7.
PMID: 38993200
PMC: 11111132.
DOI: 10.4103/jmss.jmss_30_22.
Kim D, Lee S, Hwang H, Kim S, Yun M
Nucl Med Mol Imaging. 2024; 58(4):237-245.
PMID: 38932755
PMC: 11196511.
DOI: 10.1007/s13139-024-00847-4.
Hasanzadeh A, Moghaddam H, Shakiba M, Jalali A, Firouznia K
Indian J Radiol Imaging. 2023; 33(4):514-521.
PMID: 37811185
PMC: 10556327.
DOI: 10.1055/s-0043-1772466.
Li X, Zhang W
BMC Cancer. 2023; 23(1):829.
PMID: 37670264
PMC: 10481464.
DOI: 10.1186/s12885-023-11334-y.
Wang M, Chen Y, Xu H, Zhan J, Suo D, Wang J
Cancer Sci. 2022; 114(4):1365-1377.
PMID: 36519789
PMC: 10067396.
DOI: 10.1111/cas.15692.
The value of diffusion kurtosis imaging, diffusion weighted imaging and F-FDG PET for differentiating benign and malignant solitary pulmonary lesions and predicting pathological grading.
Li Z, Luo Y, Jiang H, Meng N, Huang Z, Feng P
Front Oncol. 2022; 12:873669.
PMID: 35965564
PMC: 9373010.
DOI: 10.3389/fonc.2022.873669.
PET-CT in Clinical Adult Oncology-V. Head and Neck and Neuro Oncology.
Wiggins R, Hoffman J, Fine G, Covington M, Salem A, Koppula B
Cancers (Basel). 2022; 14(11).
PMID: 35681709
PMC: 9179458.
DOI: 10.3390/cancers14112726.
Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.
Hanzawa K, Tanaka-Okamoto M, Murakami H, Suzuki N, Mukai M, Takahashi H
PLoS One. 2022; 17(4):e0266927.
PMID: 35413075
PMC: 9004742.
DOI: 10.1371/journal.pone.0266927.
Delayed FDG PET Provides Superior Glioblastoma Conspicuity Compared to Conventional Image Timing.
Johnson J, Chen M, Rohren E, Prabhu S, Chasen B, Mawlawi O
Front Neurol. 2021; 12:740280.
PMID: 34867723
PMC: 8635110.
DOI: 10.3389/fneur.2021.740280.
Nanotechnology in Tumor Biomarker Detection: The Potential of Liganded Nanoclusters as Nonlinear Optical Contrast Agents for Molecular Diagnostics of Cancer.
Combes G, Vuckovic A, Peric Bakulic M, Antoine R, Bonacic-Koutecky V, Trajkovic K
Cancers (Basel). 2021; 13(16).
PMID: 34439360
PMC: 8393257.
DOI: 10.3390/cancers13164206.
Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.
Suzuki K, Kawai N, Ogawa T, Miyake K, Shinomiya A, Yamamoto Y
EJNMMI Res. 2021; 11(1):67.
PMID: 34291337
PMC: 8295439.
DOI: 10.1186/s13550-021-00806-6.
Correlation between FDG-PET uptake and survival in patients with primary brain tumors.
Binneboese A, Covington M, Horn K, Archibald Z, Boucher K, Morton K
Am J Nucl Med Mol Imaging. 2021; 11(3):196-206.
PMID: 34234998
PMC: 8255218.
miR-542-3p Contributes to the HK2-Mediated High Glycolytic Phenotype in Human Glioma Cells.
Kim J, Park M, Park Y, Ahn J, Sim J, Kim S
Genes (Basel). 2021; 12(5).
PMID: 33922649
PMC: 8146800.
DOI: 10.3390/genes12050633.
Quantitative protein expression of blood-brain barrier transporters in the vasculature of brain metastases of patients with lung and breast cancer.
Bao X, Wu J, Jiang J, Tien A, Sanai N, Li J
Clin Transl Sci. 2021; 14(4):1265-1271.
PMID: 33566445
PMC: 8301582.
DOI: 10.1111/cts.12978.
The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors.
Pruis I, van Dongen G, Veldhuijzen van Zanten S
Int J Mol Sci. 2020; 21(3).
PMID: 32033160
PMC: 7037158.
DOI: 10.3390/ijms21031029.
Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review.
Bonm A, Ritterbusch R, Throckmorton P, Graber J
J Neuroimaging. 2020; 30(2):139-145.
PMID: 31925884
PMC: 8300867.
DOI: 10.1111/jon.12687.
Aberrant mitochondrial function in ageing and cancer.
Whitehall J, Greaves L
Biogerontology. 2019; 21(4):445-459.
PMID: 31802313
PMC: 7347693.
DOI: 10.1007/s10522-019-09853-y.
Thirst and Drinking Paradigms: Evolution from Single Factor Effects to Brainwide Dynamic Networks.
Armstrong L, Kavouras S
Nutrients. 2019; 11(12).
PMID: 31766680
PMC: 6950074.
DOI: 10.3390/nu11122864.
Comparison of dual-time point 18F-FDG PET/CT tumor-to-background ratio, intraoperative 5-aminolevulinic acid fluorescence scale, and Ki-67 index in high-grade glioma.
Kim Y, Cho K, Jang S
Medicine (Baltimore). 2019; 98(8):e14397.
PMID: 30813140
PMC: 6408082.
DOI: 10.1097/MD.0000000000014397.
Influence of region-of-interest designs on quantitative measurement of multimodal imaging of MR non-enhancing gliomas.
Takano K, Kinoshita M, Arita H, Okita Y, Chiba Y, Kagawa N
Oncol Lett. 2018; 15(5):7934-7940.
PMID: 29725480
PMC: 5920197.
DOI: 10.3892/ol.2018.8319.